Clearside Biomedical (NASDAQ:CLSD – Get Rating) released its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.10), MarketWatch Earnings reports. Clearside Biomedical had a net margin of 0.28% and a return on equity of 0.33%. During the same period last year, the company posted ($0.13) EPS.
Shares of CLSD stock traded up $0.05 during mid-day trading on Friday, hitting $1.41. The company’s stock had a trading volume of 178,252 shares, compared to its average volume of 300,645. The company’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $2.59. Clearside Biomedical has a 52 week low of $1.30 and a 52 week high of $7.73.
Several research analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price on shares of Clearside Biomedical in a research report on Friday, March 11th. StockNews.com assumed coverage on Clearside Biomedical in a research report on Thursday, March 31st. They set a “hold” rating for the company. TheStreet lowered Clearside Biomedical from a “c” rating to a “d+” rating in a research report on Wednesday. JMP Securities lowered their target price on Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Friday, March 11th. Finally, Zacks Investment Research lowered Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Monday, May 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.25.
Clearside Biomedical Company Profile (Get Rating)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.